Double-blind, randomized, placebo-controlled Phase I Trial to determine the safety and
pharmokinetics of a single dose of CRS3123 in healthy adult volunteers. Forty healthy male
and female subjects 18 to 45 years will be admitted in 5 dosing Cohorts, 8 subjects per
Cohort. Up to two alternates may be used per dosing Cohorts for study subjects that drop out.
The primary objective of the study is to determine the safety and tolerability of escalating
doses of CRS3123 following oral administration to healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)